ClinicalTrials.gov
public full text
Public Domain
Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care
The purpose of the study is to describe the safety and efficacy outcomes of a cohort of ICU patients with severe COVID-19 respiratory disease treated with therapeutic dose Apixaban for COVID-19 at a tertiary public health care setting.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Outcomes of Patients With COVID-19 in the Intensive Care Unit#841625
- Impact of Steroids on Inflammatory Response in Covid-19#856612
- Hospital Management and 1-year Outcome of Patients Aged 70 Years and Older With Severe COVID-19#859484
- A Study for Assessing the Efficacy and Safety ParActin® in Individuals With Upper Respiratory Tract Infections#979360
- Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection#811977
Record · ID 1195687
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive